You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

  1. CORPORATE - 24-03-2017

    New company AO Kirov Plasma established in Russia

    It’s a joint venture between Kedrion Biopharma, Nacimbio and Pharmastandard

    read more 
  2. Kedrion - Feature thumbnail

    CORPORATE - 28-12-2016

    Kedrion Biopharma strengthens its presence in Russia

    Memorandum of Understanding with Russian pharmaceutical companies for a joint plasma products manufacturing program

    read more 

  3. CORPORATE - 17-06-2016

    Kedrion Biopharma consolidates presence on Russian market

    Joint venture with Nacimbio of RosTECH group for a technology transfer to Kirov plant

    read more 

  4. CORPORATE - 26-05-2016

    SIPPET study results published in the “New England Journal of Medicine”

    This investigator-initiated clinical study involved 42 hemophilia treatment centers from all over the world

    read more 

Pages

For more information please contact: pressoffice@kedrion.com